pISSN 1738-6586 / eISSN 2005-5013 / J Clin Neurol 2021;17(2):333-335 / https://doi.org/10.3988/jcn.2021.17.2.333



A Novel *KCNA1* Mutation in an Episodic Ataxia Type 1 Patient with Asterixis and Falls

Geum Bong Lee^a Ga Yeon Kim^a In Hwa Jeong^b Namhee Kim^b Jae Woo Kim^a

^aDepartments of Neurology and ^bLaboratory Medicine, Dong-A University College of Medicine, Busan, Korea

ReceivedAugust 21, 2020RevisedFebruary 5, 2021AcceptedFebruary 5, 2021

Correspondence

Jae Woo Kim, MD, PhD Department of Neurology, Parkinson's Disease Centre, Dong-A University Hospital, 26 Daesingongwon-ro, Seo-gu, Busan 49201, Korea Tel +82-51-240-2988 Fax +82-51-246-5276 E-mail jwkim@dau.ac.kr Dear Editor,

Episodic ataxia type 1(EA1) is a rare autosomal dominant ion channelopathy with incomplete penetrance that is typically characterized by brief attacks of ataxia and constant myokymia in early childhood.¹ Mutations of the *KCNA1* gene that encodes the Kv1.1 subunit of a potassium channel result in EA1.² However, a recent study found that approximately 20% of EA1 patients developed persistent cerebellar dysfunction, and various different clinical features have been reported.¹ Here we report one EA1 patient presenting with unique and atypical symptoms caused by a novel *KCNA1* mutation.

A 51-year-old female presented with progressive gait instability and intermittent falls that first appeared 8 years prior to admission. She had subsequently also developed intermittent involuntary jerking, and occasionally experienced sudden gait unsteadiness followed by falls, leading to multiple bruises. A neurologic examination revealed ataxic dysarthria, unsteady gait, and clumsiness of both hands. She showed episodes of generalized myoclonic seizure, sudden arm-dropping while eating, and falling on the floor without loss of consciousness. These episodes lasted a few seconds and occurred several times daily, and were provoked by exertion or emotional stress. An examination revealed a negative myoclonic movement when she was asked to outstretch her arms with dorsiflexion of the wrists. No vertigo, blurred vision, nausea, headache, limb weakness, parkinsonism, spasticity, myokymia, or neuromyotonia were found. Neurocognitive profiles revealed mild cognitive impairment with independence in functional activities of daily living. No family members were affected (Fig. 1A). Nerve conduction studies and EMG produced unremarkable findings. The EEG revealed generalized polyspike discharges at 3–5 Hz (Fig. 1B). Brain MRI revealed cerebellar atrophy (Fig. 1C).

Genetic testing was performed in the patient using a gene panel containing 30 genes known to be related to hereditary ataxia (*ANO10, APTX, ATM, C10orf2, CACNA1A, CAC-NB4, COQ8A, CYP27A1, FGF14, ITPR1, KCNA1, KCNC3, KCND3, PEX7, PNKP, PNPLA6, POLG, PRKCG, SACS, SETX, SIL1, SLC52A2, SNX14, SPG7, SPTBN2, SYNE1, TMEM240, TTBK2, TTPA, and WFS1). The patient was found to have a novel heterozygous mutation of <i>KCNA1*: a frameshift mutation of c.791del (p.Pro264LeufsTer 10) (NM_000217.2). The detected variant was classified as pathogenic along with PVS1 (null variant), PM2 (absent from controls), and PP3(computational predictions) according to American College of Medical Genetics and Genomics guidelines.³ Mutation prediction analysis using the PolyPhen-2 tool showed the novel variant to be probably damaging (Fig. 1D). *KCNA1* analysis in her unaffected younger brother was negative.

EA1 is mainly caused by missense genetic mutations,⁴ whereas the present patient had a novel frameshift mutation of *KCNA1*. Although EA1 is the most common diagnosis resulting from a *KCNA1* mutation, patients can also exhibit various clinical features.⁵ Besides recurrent ataxic attacks, our patient displayed several peculiar symptoms. She experienced generalized

[©] This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

JCN A Novel Mutation in a Korean EA1 Patient




Fig. 1. Pedigree, EEG, brain MRI, and next-generation sequencing of the *KCNA1* mutation. A: There was no family history on the pedigree of the proband. B: EEG signals associated with myoclonic jerks reveal polyspike discharges at 3–5 Hz. C: Brain MRI showed cerebellar atrophy. D: Next-generation sequencing confirmed the heterozygous status for the c.791del (p.Pro264LeufsTer 10) mutation of *KCNA1*.

myoclonic movement,⁴ which was considered to be myoclonic epilepsy based on the EEG findings. She also showed asterixis presenting as sudden wrist- or arm-dropping and falls, which had reportedly never occurred previously. Furthermore, myokymia and neuromyotonia were not observed, which are commonly reported in EA1.¹ Persistent cerebellar dysfunction supported by prominent cerebellar atrophy in brain MRI was found, which is unusual in EA1.¹ The frequency of ataxic attacks and myoclonic epilepsy decreased dramatically with levetiracetam administration, but not with acetazolamide. Our proband presented mild cognitive dysfunction related to epileptic encephalopathy, which is also a rare symptom of EA1.⁶ To validate the complex phenotype of the causative *KCNA1* mutation, we applied genetic and nongenetic tests to exclude other mutations and the possibilities that the complex phenotype was due to additional disorders. We performed other

Lee GB et al.

genetic tests including those of spinocerebellar ataxia 1, 2, 3, 6, 7, 8, and 17 genes, DRPLA, and RRNP related to progressive cerebellar ataxia, which were all negative (Supplementary Table 1 in the online-only Data Supplement). Several genes responsible for progressive myoclonic epilepsy with cerebellar ataxia were also negative (Supplementary Table 1 in the online-only Data Supplement). The results of toxicity, metabolism, and neoplasia tests such as for tumor markers, thyroid hormones/antibodies, and vitamins were normal. Furthermore, the patient was negative for serum autoimmune/ paraneoplastic antibodies (anti-Hu, anti-Ri, anti-Yo, anti-amphiphysin, anti-CV2, anti-PNMA1, anti-recoverin, anti-SOX1, and anti-titin) and cerebrospinal fluid malignancy. Nongenetic tests were not contributory.

Here we have expanded the genetic and clinical spectrum of EA with asterixis and falls caused by KCNA1 mutations. We report the first Korean EA1 patient with a novel KCNA1 mutation. Understanding the pathomechanism of unusual clinical features in this case will require more research into the genotype-phenotype correlation.

Supplementary Materials

The online-only Data Supplement is available with this article at https://doi.org/10.3988/jcn.2021.17.2.333.

Author Contributions

Conceptualization: Jae Woo Kim, Geum Bong Lee. Data curation: Namhee Kim, In Hwa Jeong. Formal analysis: Jae Woo Kim, Namhee Kim. Supervision: Jae Woo Kim. Visualization: In Hwa Jeong, Ga Yeon Kim Writingoriginal draft: Geum Bong Lee, Ga Yeon Kim. Writing-review & editing:

Jae Woo Kim.

ORCID iDs _

Geum Bong Lee	https://orcid.org/0000-0001-8851-6332
Ga Yeon Kim	https://orcid.org/0000-0003-4314-7646
In Hwa Jeong	https://orcid.org/0000-0001-8383-8228
Namhee Kim	https://orcid.org/0000-0003-0844-5058
Jae Woo Kim	https://orcid.org/0000-0003-3054-6306

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Acknowledgements

None

REFERENCES

- 1. Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain 2014;137(Pt 4):1009-1018.
- 2. D'Adamo MC, Liantonio A, Rolland JF, Pessia M, Imbrici P. Kv1.1 channelopathies: pathophysiological mechanisms and therapeutic approaches. Int J Mol Sci 2020;21:2935.
- 3. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424.
- 4. Paulhus K, Ammerman L, Glasscock E. Clinical spectrum of KCNA1 mutations: new insights into episodic ataxia and epilepsy comorbidity. Int I Mol Sci 2020;21:2802.
- 5. Kipfer S, Strupp M. The clinical spectrum of autosomal-dominant episodic ataxias. Mov Disord Clin Pract 2014;1:285-290.
- 6. Rogers A, Golumbek P, Cellini E, Doccini V, Guerrini R, Wallgren-Pettersson C, et al. De novo KCNA1 variants in the PVP motif cause infantile epileptic encephalopathy and cognitive impairment similar to recurrent KCNA2 variants. Am J Med Genet A 2018;176:1748-1752.